Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials
- 5 October 2022
- Vol. 40 (46) , 6599-6606
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- A Recombinant Vesicular Stomatitis Virus Ebola VaccineNew England Journal of Medicine, 2017
- Phase 1 Trials of rVSV Ebola Vaccine in Africa and EuropeNew England Journal of Medicine, 2016
- Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibodyScience, 2016
- Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 YearsThe Journal of Infectious Diseases, 2016
- Long-term Persistence of Zoster Vaccine EfficacyClinical Infectious Diseases, 2014
- Risk Factors for Zaireebolavirus–Specific IgG in Rural Gabonese PopulationsThe Journal of Infectious Diseases, 2011
- The Xs and Y of immune responses to viral vaccinesThe Lancet Infectious Diseases, 2010
- Ebola and Marburg virus antibody prevalence in selected populations of the Central African RepublicMicrobes and Infection, 2000
- Haemorrhagic fever virus activity in equatorial Africa: distribution and prevalence of filovirus reactive antibody in the Central African RepublicTransactions of the Royal Society of Tropical Medicine and Hygiene, 1993
- Antibody prevalence against haemorrhagic fever viruses in randomized representative central African populationsResearch in Virology, 1989